MAPT and breast cancer: Estrogen receptor signaling has also been shown to influence the expression of microtubule-associated protein tau (MAPT) such that the ER inhibitor fulvestrant can promote MAPT downregulation and thereby increase breast cancer cell sensitivity to taxane-based chemotherapy [41].